Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69daa30b0f32475823a3d6e4 — DOI: https://doi.org/10.1056/nejmoa1006448

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>· 2009 · 1,875 citations
2. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of <i>ALK</i> -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry· 2010 · 423 citations
3. Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer· 2009 · 181 citations
4. Oncogenic protein tyrosine kinases· 2004 · 138 citations
5. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066· 2009 · 205 citations